Cargando…
Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?
Autores principales: | Chhatwal, Jagpreet, Basu, Anirban |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933136/ https://www.ncbi.nlm.nih.gov/pubmed/35315330 http://dx.doi.org/10.1016/j.jval.2022.02.002 |
Ejemplares similares
-
COVID-19 Health Economics: Looking Back and Scoping the Future
por: Postma, Maarten J., et al.
Publicado: (2022) -
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
por: Whittington, Melanie D., et al.
Publicado: (2022) -
A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales
por: Rafia, Rachid, et al.
Publicado: (2022) -
Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States
por: Basu, Anirban, et al.
Publicado: (2021) -
Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review
por: Vandepitte, Sophie, et al.
Publicado: (2021)